Valuation: VolitionRx Limited

Market Cap 2.54M 2.29M 2.13M 1.93M 3.63M 242M 3.65M 25.6M 10M 126M 9.54M 9.34M 404M P/E 2026 *
-0.09x
P/E 2027 * -0.18x
Enterprise Value 2.54M 2.29M 2.13M 1.93M 3.63M 242M 3.65M 25.6M 10M 126M 9.54M 9.34M 404M EV / Sales 2026 *
0.93x
EV / Sales 2027 * 0.27x
Free-Float
94.07%
Yield 2026 *
-
Yield 2027 * -
1 day-3.09%
1 week-20.80%
Current month-30.62%
1 month-42.65%
3 months-85.91%
6 months-94.41%
Current year-96.50%
1 week 0.17
Extreme 0.1748
0.23
1 month 0.17
Extreme 0.1748
0.3
Current year 0.17
Extreme 0.1748
7.73
1 year 0.17
Extreme 0.1748
10.31
3 years 0.17
Extreme 0.1748
24.6
5 years 0.17
Extreme 0.1748
82.8
10 years 0.17
Extreme 0.1748
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
28/09/26 Tax

Executive/Senior Manager

-284 0.0010%
28/09/26 Tax

Chief Operating Officer

-608 0.0022% -
17/03/26
Concord International, Inc.
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-3.09%-20.80%-98.06%-98.64% 2.54M
-2.01%-7.86%+60.74%+70.97% 68.92B
+3.84%-11.02%+8.59%+57.43% 51.9B
+3.35%+1.42%+11.85%+40.01% 48.73B
+0.51%+1.51%+27.96%+31.43% 43.13B
+2.70%-3.66%+307.41%+547.01% 41.48B
+0.69%-3.44%+9.52%+96.59% 39.96B
+0.06%-2.02%+11.25%+43.27% 30.6B
-2.13%-9.94%+35.56%-0.57% 26.01B
-0.39%-6.92%-13.60%-14.40% 22.27B
Average +0.36%-6.20%+36.12%+77.31% 37.3B
Weighted average by Cap. +0.87%-4.28%+54.99%+103.79%

Financials

2026 *2027 *
Net sales 2.72M 2.45M 2.29M 2.07M 3.89M 259M 3.91M 27.43M 10.71M 135M 10.23M 10M 433M 9.27M 8.34M 7.78M 7.05M 13.24M 883M 13.32M 93.39M 36.47M 458M 34.82M 34.07M 1.47B
Net income -22.25M -20.01M -18.67M -16.92M -31.77M -2.12B -31.97M -224M -87.49M -1.1B -83.54M -81.73M -3.53B -18.42M -16.56M -15.45M -14.01M -26.3M -1.75B -26.46M -185M -72.42M -910M -69.15M -67.65M -2.93B
Net Debt - -
Projected Income Statement - Annual - VolitionRx Limited
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
14/10/26 US$0.1790 -3.09% 993,183
13/10/26 US$0.1847 -9.06% 1,844,149
12/10/26 US$0.2031 -3.88% 777,557
09/10/26 US$0.2113 -3.69% 1,082,015
08/10/26 US$0.2194 -2.92% 825,468
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - VolitionRx Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.1790USD
Average target price
13.62USD
Spread / Average Target
+7,510.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - VolitionRx Limited
  1. Stock Market
  2. Stocks
  3. VNRX Stock